X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4930) 4930
Publication (598) 598
Newsletter (175) 175
Book Review (39) 39
Dissertation (19) 19
Book Chapter (18) 18
Conference Proceeding (6) 6
Magazine Article (2) 2
Reference (2) 2
Trade Publication Article (2) 2
Book / eBook (1) 1
Newspaper Article (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
gefitinib (4464) 4464
humans (3271) 3271
index medicus (2953) 2953
oncology (2777) 2777
mutation (1834) 1834
lung neoplasms - drug therapy (1580) 1580
lung cancer (1576) 1576
erlotinib (1512) 1512
lung neoplasms - genetics (1393) 1393
cancer (1389) 1389
female (1388) 1388
chemotherapy (1304) 1304
carcinoma, non-small-cell lung - drug therapy (1265) 1265
acquired-resistance (1232) 1232
receptor, epidermal growth factor - genetics (1210) 1210
egfr (1171) 1171
epidermal growth factor (1168) 1168
male (1149) 1149
lung cancer, non-small cell (1088) 1088
cell line, tumor (1081) 1081
carcinoma, non-small-cell lung - genetics (1041) 1041
lung neoplasms - pathology (1014) 1014
resistance (1011) 1011
receptor, epidermal growth factor - antagonists & inhibitors (980) 980
middle aged (973) 973
growth-factor receptor (926) 926
cell lung-cancer (914) 914
aged (910) 910
mutations (807) 807
tyrosine kinase inhibitors (785) 785
antineoplastic agents - therapeutic use (781) 781
respiratory tract diseases (780) 780
adenocarcinoma (777) 777
protein kinase inhibitors - therapeutic use (772) 772
genetic aspects (762) 762
kinases (759) 759
animals (758) 758
antineoplastic agents - pharmacology (752) 752
carcinoma, non-small-cell lung - pathology (747) 747
quinazolines - pharmacology (746) 746
non-small cell lung cancer (738) 738
research (725) 725
tyrosine (712) 712
tumors (705) 705
care and treatment (703) 703
protein kinase inhibitors - pharmacology (702) 702
adult (648) 648
quinazolines - therapeutic use (625) 625
drug resistance, neoplasm (619) 619
receptor, epidermal growth factor - metabolism (619) 619
epidermal growth factor receptor (582) 582
tyrosine kinase inhibitor (580) 580
drug resistance (567) 567
therapy (567) 567
cancer therapies (561) 561
expression (558) 558
apoptosis (548) 548
open-label (547) 547
respiratory system (537) 537
epidermal growth factor receptors (534) 534
mice (527) 527
drug resistance, neoplasm - genetics (516) 516
aged, 80 and over (511) 511
lung neoplasms - metabolism (500) 500
health aspects (499) 499
cell biology (468) 468
nsclc (465) 465
analysis (463) 463
egfr mutations (438) 438
erlotinib hydrochloride (433) 433
growth-factor-receptor (433) 433
lung-cancer (427) 427
signal transduction (425) 425
treatment outcome (419) 419
metastasis (412) 412
cell proliferation - drug effects (410) 410
survival (408) 408
1st-line treatment (407) 407
proteins (406) 406
prognosis (401) 401
pharmacology & pharmacy (392) 392
sensitivity (391) 391
erbb receptors - genetics (375) 375
article (373) 373
gefitinib resistance (372) 372
adenocarcinoma - genetics (371) 371
non-small cell lung carcinoma (370) 370
drug therapy (369) 369
patients (368) 368
carcinoma, non-small-cell lung - metabolism (362) 362
egfr mutation (360) 360
activation (356) 356
inhibitors (350) 350
development and progression (348) 348
neoplasms (337) 337
protein-tyrosine kinase (337) 337
adenocarcinoma - drug therapy (336) 336
gene expression (333) 333
phosphorylation (333) 333
medicine (326) 326
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5045) 5045
French (30) 30
Chinese (23) 23
Korean (11) 11
German (8) 8
Japanese (7) 7
Spanish (5) 5
Polish (3) 3
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Cancer Research, ISSN 1078-0432, 01/2013, Volume 19, Issue 1, pp. 279 - 290
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2013, Volume 368, Issue 25, pp. 2395 - 2401
Journal Article
Nuclear Medicine and Biology, ISSN 0969-8051, 2009, Volume 36, Issue 3, pp. 239 - 246
Journal Article
Nature Genetics, ISSN 1061-4036, 08/2012, Volume 44, Issue 8, pp. 852 - 860
Human non-small cell lung cancers (NSCLCs) with activating mutations in EGFR frequently respond to treatment with EGFRtargeted tyrosine kinase inhibitors... 
GEFITINIB | RECEPTOR TYROSINE KINASES | MET AMPLIFICATION | GROWTH | GENETICS & HEREDITY | ACQUIRED-RESISTANCE | MUTATIONS | NF-KAPPA-B | TUMORS | MUTANT EGFR | ERLOTINIB | Erlotinib Hydrochloride | Proto-Oncogene Proteins c-met - metabolism | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Humans | Lung Neoplasms - metabolism | Middle Aged | Lung Neoplasms - pathology | Male | Intercellular Signaling Peptides and Proteins - metabolism | Epithelial-Mesenchymal Transition | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Proto-Oncogene Proteins - metabolism | Proto-Oncogene Proteins - antagonists & inhibitors | Signal Transduction | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Intercellular Signaling Peptides and Proteins - genetics | Proto-Oncogene Proteins - genetics | Receptor Protein-Tyrosine Kinases - metabolism | Proto-Oncogene Proteins c-met - genetics | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Animals | Receptor Protein-Tyrosine Kinases - genetics | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Enzyme Activation | Mutation | Quinazolines - pharmacology | Erlotinib | Physiological aspects | Genetic aspects | Research | Lung cancer, Non-small cell | Drug therapy | Health aspects | Protein kinases | Studies | Medical research | Rodents | Lung cancer | Genomics | Kinases | Gene expression | Acquisitions & mergers | Tumors
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2013, Volume 19, Issue 8, pp. 2240 - 2247
Journal Article
Journal Article
Cancer Discovery, ISSN 2159-8274, 12/2013, Volume 3, Issue 12, pp. 1404 - 1415
Patients with non-small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine... 
CELL LUNG-CANCER | MET AMPLIFICATION | ONCOLOGY | FACTOR RECEPTOR MUTATIONS | ACQUIRED-RESISTANCE | TYROSINE KINASE INHIBITOR | T790M MUTATION | OPEN-LABEL | AKT INHIBITOR | GEFITINIB RESISTANCE | AXL KINASE | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Humans | Drug Resistance, Neoplasm | Epithelial-Mesenchymal Transition - drug effects | Lung Neoplasms - pathology | Antineoplastic Agents - administration & dosage | Molecular Targeted Therapy | Receptor, Epidermal Growth Factor - metabolism | HEK293 Cells | Female | Antineoplastic Agents - pharmacology | Acrylamides - pharmacology | Mutant Proteins - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidines - administration & dosage | Mice, Transgenic | Mutant Proteins - metabolism | Pyrimidines - pharmacology | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Animals | Acrylamides - administration & dosage | Mice, Nude | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Cell Proliferation - drug effects | Mice | Mice, Inbred BALB C | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Drug Screening Assays, Antitumor | T790M | drug resistance | NSCLC | EMT | EGFR
Journal Article
Journal Article
Seminars in Cancer Biology, ISSN 1044-579X, 2016, Volume 45, pp. 36 - 49
Abstract Darwinian selection is also applicable when antibiotics, the immune system or other host factors shape the repertoire of microorganisms, and... 
Hematology, Oncology and Palliative Medicine | Brigatinib | Crizotinib | Nilotinib | Dasatinib | Imatinib | Dabrafenib | Osimertinib | Rociletinib | Ibrutinib | Trametinib | Alectinib | Vemurafenib | Erlotinib | Lorlatinib | Acalabrutinib | Gefitinib | Ceritinib | TARGETED THERAPY | ANAPLASTIC LYMPHOMA KINASE | CHRONIC LYMPHOCYTIC-LEUKEMIA | MUTANT COLORECTAL-CANCER | BCR-ABL | ACQUIRED-RESISTANCE | NON-ONCOGENE ADDICTION | CHRONIC MYELOID-LEUKEMIA | CELL LUNG-CANCER | BRUTONS TYROSINE KINASE | ONCOLOGY | Neoplasms - metabolism | Tumor Microenvironment - drug effects | Humans | Antineoplastic Agents - therapeutic use | Biomarkers, Tumor | Cell Transformation, Neoplastic - metabolism | Neoplasms - drug therapy | Tumor Microenvironment - immunology | Drug Resistance, Neoplasm - genetics | Animals | Genetic Fitness | Tumor Microenvironment - genetics | Neoplasms - genetics | Cell Transformation, Neoplastic - genetics | Protein Kinase Inhibitors - therapeutic use | DNA Repair | Antineoplastic Agents - pharmacology | Protein Kinase Inhibitors - pharmacology | Mutation | Neoplasms - pathology | Clonal Evolution | Tyrosine | Cell death | Analysis | Therapeutics | Drug therapy | Drug resistance | Protein kinases | Cancer | Natural selection | Homeopathy | Materia medica and therapeutics | Antimitotic agents | Antineoplastic agents
Journal Article
Journal Article